CD38 overexpression drives glioblastoma progression via L1CAM/ICAM1/JAK-STAT-Driven tumor microenvironment rewiring

Key Points

• To investigate the role of CD38 overexpression in glioblastoma and its impact on tumor progression and immune environment.
• Analysis of CD38 expression levels in glioblastoma tissues
• Assessment of tumor microenvironment changes
• Evaluation of daratumumab efficacy in clinical trials
• CD38 overexpression correlates with increased immunosuppressive factors in the tumor microenvironment
• Daratumumab shows preliminary efficacy in patients with elevated CD38 levels
• Findings suggest CD38 as a potential therapeutic target for glioblastoma

Abstract